Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...
The FDA has granted priority review to a new drug application (NDA) seeking the approval of sonrotoclax (BGB-11417; BeOne ...
Donor type strongly influences survival, relapse risk, and GVHD after high-risk acute myeloid leukaemia stem cell transplantation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback